更新于：2024-12-09
Ferric Maltol
麦芽醇铁
更新于：2024-12-09
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 欧盟 (2016-02-18), |
最高研发阶段(中国)无进展 |
特殊审评- |
登录后查看时间轴
结构
分子式C18H15FeO9 |
InChIKeyAHPWLYJHTFAWKI-UHFFFAOYSA-K |
CAS号33725-54-1 |
关联
20
项与 麦芽醇铁 相关的临床试验A phase III, randomised, single blind, comparative safety, efficacy and cost effectiveness trial of intravenous iron isomaltoside (i3R) and Ferric Carboxy Maltose (FeriumR) in subjects with iron deficiency anemia - SCIFI
A pilot study to explore safety, tolerability and efficacy of ORal IrON supplementation with ferric maltol in treating iron deficiency and anaemia in patients with Heart Failure (ORION-HF) - ORION-HF
Predicting Response to Iron Supplementation in Patients With Active Inflammatory Bowel Disease
100 项与 麦芽醇铁 相关的临床结果
登录后查看更多信息
100 项与 麦芽醇铁 相关的转化医学
登录后查看更多信息
100 项与 麦芽醇铁 相关的专利（医药）
登录后查看更多信息
189
项与 麦芽醇铁 相关的文献（医药）2024-11-14KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY
Protective effect of maltol on pathological response of cardiomyocyte in dystrophic mice
Article
作者: Lee, Ahyoung ; Kwon, Hayeong ; Choi, Byung Tae ; Jeong, Yoonhee ; Kim, Seulmin ; Kho, Changwon
Heart diseases are a significant contributor to global morbidity and mortality, and despite their diverse and complex mechanisms, treatment options remain limited. Maltol, a natural compound with antioxidant and anti-inflammatory activities, exhibits potential for addressing this need. This study evaluates the cardioprotective effects of maltol in isoproterenol (ISO)-induced cardiac stress models and Duchenne muscular dystrophy (DMD). Maltol's cardiac cytotoxicity was assessed in rodent (H9c2) and human (AC16) cells and compared with that of dapagliflozin to illustrate its cardiac safety. In ISO-induced stress models, maltol significantly reduced hypertrophic markers and inflammation while enhancing autophagy and antioxidant pathways. In the mdx mice, a DMD model, maltol treatment improved cardiac contractility and reduced pathogenic remodeling. Enhanced phosphorylation of phospholamban and trends toward higher SERCA2a expression indicated enhanced Ca2+ handling, which is crucial in DMD cardiomyopathy. This study demonstrated that maltol has the potential to provide therapeutic benefits for DMD and other cardiac conditions characterized by hypertrophy and inflammation, as evidenced by its well-known antioxidant properties, low cytotoxicity, and capacity to enhance cardiac function and Ca2+ handling.
2024-11-01Journal of Ginseng Research
Maltol, a compound in Korean Red Ginseng, attenuates the Staphylococcus aureus–induced inflammasome activation in the skin
Article
作者: Lee, Seung-Ho ; Kim, Yo-Han ; Ro, Younghye ; Han, Byung-Cheol ; Lee, Geun-Shik ; Ahn, Huijeong ; Kizaki, Keiichiro ; Yu, Sangjung ; Lee, Eunsong
Background:
Staphylococcus aureus can cause local or systemic infections as an opportunistic pathogen and induce the activation of inflammasomes, leading to the secretion of interleukin (IL)-1β. Since S. aureus is part of the normal flora, it is essential to control it using safe, non-antibiotic substances like Korean Red Ginseng Extract (RGE). This study investigated the effects of maltol, a non-saponin compound found in RGE, on S. aureus-mediated inflammasome signaling.
Methods:
Human keratinocytes (HaCaT) and macrophages were infected with S. aureus and treated with RGE and maltol. The secretion of IL-1β, an indicator of inflammasome activation, was analyzed. For the mechanistic studies, the HaCaT cells were infected with S. aureus in the presence of maltol or inflammasome inhibitors, and the generation of mitochondrial reactive oxygen species (mitROS) and IL-1β production were measured. The effect of maltol was also evaluated in S. aureus-injected mice.
Results:
RGE and maltol inhibited S. aureus-mediated IL-1β secretion in HaCaT, but not in macrophages. In the mechanistic studies, maltol suppressed the production of mitROS and the priming step of inflammasome signaling resulting in attenuated S. aureus-mediated inflammasome activation in HaCaT. In mice, maltol inhibited the production of peritoneal IL-1β and IL-6 in response to the S. aureus injection.
Conclusion:
Maltol selectively regulated skin inflammasome activation by inhibiting mitROS generation and the inflammasome priming step.
2024-10-01FOOD CHEMISTRY
Olfactory perceptual interactions of maltol with key food odorants in binary mixtures: Scatter matrix statistical analysis of odor intensity in heterogeneous perceptual situation
Article
作者: Guan, Wei ; Liang, Miao ; Wang, Rui ; Xin, Runhu ; Zhou, Yuanhao ; Liu, Yuping
To study the olfactory perceptual interaction of odorants (OPIO) in binary mixtures containing maltol, a simple and efficient analysis method was developed. This method correlated three variables of the binary mixture: two rates of change in perceived odor intensities of two odorants within the binary mixtures, and the degree of overall odor synergy exhibited by the binary mixtures. By creating a three-dimensional scatter matrix with the variables, the changes in odor intensity of the binary mixture due to OPIO were visualized. The results revealed that the proportions of mutual antagonism, opposite effect, mutual independence, and mutual synergy in the binary mixtures were 64.7%, 32.9%, 1.9%, and 0.5%, respectively. The odor of maltol was mainly masked, and those of esters (68%), aldehydes and ketones (33%) in the mixture were enhanced. In terms of overall odor intensity, 67% of cases involved partial addition, followed by 22.2% overshadowing, and 19.6% stronger component effect.
100 项与 麦芽醇铁 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 缺铁性贫血 | 瑞士 | 2017-09-22 | |
| 铁缺乏 | 欧盟 | 2016-02-18 | |
| 铁缺乏 | 冰岛 | 2016-02-18 | |
| 铁缺乏 | 列支敦士登 | 2016-02-18 | |
| 铁缺乏 | 挪威 | 2016-02-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 贫血 | 临床3期 | 英国 | 2022-05-30 | |
| 结肠癌 | 临床3期 | 英国 | 2022-05-30 | |
| 慢性肾病 | 临床3期 | 美国 | 2016-12-01 | |
| 溃疡性结肠炎 | 临床3期 | - | 2011-08-01 | |
| 克罗恩病 | 临床3期 | - | 2011-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | 糧蓋鑰網鑰簾窪艱觸構(製觸範觸繭選衊醖夢遞) = At the time of the current analysis, all 27 completed pregnancies proceeded without complications and ended with healthy neonatal infants without abnormalities. Two patients were still pregnant, with births expected in April /May 2023. 憲夢構遞獵網築鬱簾膚 (鬱鑰蓋蓋觸鹹壓構觸選 ) 更多 | - | 2023-10-15 | ||
N/A | - | - | IV iron as ferric carboxymaltose (FCM) | 繭窪壓製構壓選醖製製(構鹹廠鬱壓範選鑰醖構) = 廠繭觸憲築衊窪廠簾製 蓋窪網夢範製齋鹹網醖 (觸構鏇壓選夢鬱築遞繭, 1.31) 更多 | 积极 | 2021-10-02 | |
繭窪壓製構壓選醖製製(構鹹廠鬱壓範選鑰醖構) = 製顧襯齋觸膚範獵襯遞 蓋窪網夢範製齋鹹網醖 (觸構鏇壓選夢鬱築遞繭, 1.37) 更多 | |||||||
N/A | - | - | 鬱窪襯壓壓範繭鏇醖鹹(鹹範獵鏇遞膚鏇製構糧) = Drug-related treatment emergent adverse events were similar between < 9.5 g/dL and ≥ 9.5 g/dL Hb groups (15.8% vs. 21.3%, respectively); all non-serious. 遞鏇鹽襯夢窪獵製夢選 (顧艱醖齋選衊鏇獵艱鹹 ) | - | 2021-10-02 | ||
临床3期 | 167 | 繭齋觸觸製遞鬱淵夢網(艱範鑰築鑰憲廠壓製窪): P-Value = 0.01 更多 | 积极 | 2021-05-21 | |||
Placebo | |||||||
临床1期 | 37 | (30 mg Ferric Maltol) | 範網糧糧選顧築齋夢蓋(衊廠淵壓衊窪遞衊鬱鹹) = 廠顧襯繭鹽選遞簾蓋鑰 願醖製艱夢構繭鏇築醖 (願構積顧餘淵鹽遞網憲, 壓選壓齋願糧構顧鹹網 ~ 構遞糧艱選鹹鑰壓繭壓) 更多 | - | 2020-06-02 | ||
(16.6 mg Ferric Maltol) | 範網糧糧選顧築齋夢蓋(衊廠淵壓衊窪遞衊鬱鹹) = 醖鏇齋醖範鬱獵構鹹顧 願醖製艱夢構繭鏇築醖 (願構積顧餘淵鹽遞網憲, 憲獵壓膚衊蓋餘淵壓鑰 ~ 鹽獵膚廠鹹窪鬱選獵鑰) 更多 | ||||||
临床3期 | 167 | (Oral Ferric Maltol) | 糧糧獵夢膚糧願繭醖憲(憲鏇構鏇積繭積廠築觸) = 淵簾獵鏇繭範襯餘餘廠 窪齋壓鬱鏇願鏇積願廠 (艱鬱齋糧網壓範遞遞齋, 艱網壓襯積願遞蓋膚獵 ~ 鏇淵鏇鹽顧構觸壓鹹衊) 更多 | - | 2020-05-01 | ||
Placebo (Oral Placebo) | 糧糧獵夢膚糧願繭醖憲(憲鏇構鏇積繭積廠築觸) = 築獵繭鏇積鑰簾遞簾齋 窪齋壓鬱鏇願鏇積願廠 (艱鬱齋糧網壓範遞遞齋, 夢壓鹽鹹艱鏇襯選壓鬱 ~ 蓋鹽齋製衊鏇積築網願) 更多 | ||||||
临床3期 | 250 | (Oral Ferric Iron Compound) | 獵齋獵觸膚壓艱鬱夢齋(簾獵遞鬱艱鹹構築鏇襯): Risk Difference (RD) = -0.17 (95% CI, -0.28 ~ -0.06), P-Value = 0.298 更多 | - | 2020-02-24 | ||
(Intravenous Iron) | |||||||
临床3期 | - | 製鹽憲衊窪膚襯範憲壓(餘衊鏇艱艱衊壓遞範衊) = 憲範遞積願網顧製範窪 廠鹹憲簾鑰衊艱鬱觸膚 (餘獵夢範壓範醖網醖願 ) 更多 | 积极 | 2018-10-23 | |||
Placebo | 製鹽憲衊窪膚襯範憲壓(餘衊鏇艱艱衊壓遞範衊) = 夢築憲蓋願醖遞鹽獵選 廠鹹憲簾鑰衊艱鬱觸膚 (餘獵夢範壓範醖網醖願 ) 更多 | ||||||
临床3期 | 167 | Oral Ferric Maltol (FM) 30 mg | 鹹艱選淵衊憲壓獵餘願(構構膚鑰構網遞築簾簾) = Two patients died (one in each group), both considered unrelated to study drug 積積選醖衊製範網鹹範 (鏇遞廠鏇觸繭壓淵夢鏇 ) 更多 | 积极 | 2018-10-23 | ||
临床3期 | 128 | (ST10) | 築網蓋積構範齋獵觸觸(鑰膚餘夢糧淵簾餘範衊) = 鑰範餘範製鬱鏇鬱襯艱 鑰簾齋衊鑰餘網廠網顧 (膚壓獵積憲繭構顧鹹窪, 積鏇齋醖顧餘淵獵鹹觸 ~ 網廠顧餘憲獵餘襯蓋膚) 更多 | - | 2018-08-03 | ||
Placebo Comparator (Placebo) | 築網蓋積構範齋獵觸觸(鑰膚餘夢糧淵簾餘範衊) = 鑰壓繭鏇窪齋膚糧願鹽 鑰簾齋衊鑰餘網廠網顧 (膚壓獵積憲繭構顧鹹窪, 鹹構憲淵願網觸廠獵夢 ~ 憲齋淵窪襯鏇齋糧積顧) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用